Jump to content

MaryPDX

Members
  • Content Count

    69
  • Joined

  • Last visited

  • Days Won

    4
  • Country

    United States

MaryPDX last won the day on January 31 2018

MaryPDX had the most liked content!

Profile Information

  • Gender
    Not Telling
  • Location
    Oregon
  • Occupation
    Medical Technologist

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. We have been using WB for traumas for a few months. Ours are low titer (from ARC) and we have set up our system to allow WB to be given to any type. Also, we are allowed to give type specific red cells afterward. We can give any amount necessary while they are in Trauma/Massive Transfusion Protocol status. We limit this to adults only. Males and Females 45 and > get O+ Females <45 get O= (they can be given Rh Pos with Pathologist approval) These WB products are collected using a system from Terumo (allows leukoreduction, but spares platelets). When the product has 7 days left to expire, we convert the WB into a packed RBC which can be given to almost anyone.
  2. The units we will be getting are leukocyte reduced.
  3. Correct. We start the first week of July 10 O+ and 10 O=
  4. I just answered this question. My Score PASS  
  5. We've been doing it for over 15 years (from the time we had Ortho's gel cards). Whatever validation was recorded, it's from eons ago and I wasn't involved with that one. I would imagine it was similar to the validation done with the DAT method in gel cards (from my other post in that section)
  6. Yes it correlated very well. As far as the Grifols DC card (DAT card), I've heard early 2018, but I haven't seen anything yet from FDA that it's licensed.
  7. Yes. We have 2 Erytras, so T&S, ABID, xm (AHG ones, not IS), unit retypes...
  8. We use Immucor cells in Grifols gel cards and they work fine. (we use them for additional rule outs when necessary, not the first line of the ABID.)
  9. Did a total of 20 tests (combination of QC and patients). Ran the C3 test manually (tube method, which was our standard SOP), and in the buffer gel cards. Results of testing using both methods were recorded on paper for the Pathologist, Manager and our Technical Coordinator to view. They all had to sign off on the new method before the procedure was updated. Procedure of buffer gel card method: 1. Bring your reagents, QC and patients to room temperature. 2. Make a 0.8% red cell suspension (of QC and patients.) 3. For QC, you will need a POS, NEG and a control well (pos control cells only in the control well). 4. For patients you will need 2 wells, one that you will add red cells and reagent to, other patient cells only. The reason for the red cell + buffer only wells is to ensure that no spontaneous agglutination is happening. 5. Add 50ul of red cells to wells 6. Add 25ul of anti-C3 reagent to reagent wells only (DO NOT add reagent to buffer only control wells) 7. Incubate 5 min. RT 8. Spin in appropriate gel centrifuge. 9. Record results. Just an FYI, before you turn your findings in, make a copy of the paperwork, just in case someone loses it. (speaking from experience here). Hope this helps. Mary
  10. We bill for all crossmatches performed.
  11. Here they order EMERRGENCY blood in EPIC, which prompts the pager to go off. If they order a massive transfusion, the LIFT team also get activated (dedicated people that will run the products from here to where patient is located. Floors still call us to give us a heads up that they are placing the order.
  12. Our facility hasn't started CD47 yet, but anticipate that may happen in 2018. I've been dredging through the internet to find anything, which is how I found the NY blood center pdf. Besides the use of Immucors Gamma-clone IgG antisera (for antibody screens), I haven't seen anything mentioned on how to avoid it. I was thinking along the line of using Platelets (which have cd47 on them) to remove the antibody, but have seen nothing regarding if anyone has tried this. The search continues....
  13. http://nybloodcenter.org/media/filer_public/2017/10/04/2017aabbpostervelliquetteserological_observationsfinalcp246.pdf Apparently, weakly pos to negative DATs are common. Because the antibody covers cd47, the body sees the lack of cd47 and targets the cell for destruction.
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.